

1 Article

2 **A randomized, double-blind, placebo-controlled decentralized**
3 **trial to assess sleep, health outcomes, and overall well-being in**
4 **healthy adults reporting disturbed sleep, taking a melato-**
5 **nin-free supplement.**

6 *Antonija Kolobaric^{1,2}, *Susan J Hewlings¹, Corey Bryant¹, Chris Colwell³, Chris D'Adamo⁴, Bernard Rosner⁵,
7 Jeff Chen¹, and Emily K Pauli¹

8 ¹ Radicle Science, Inc, ² University of Pittsburgh, ³ University of California - Los Angeles, ⁴ University of Mar-
9 yland, ⁵ Harvard University

10 * Correspondence: susan.hewlings@radiclescience.com

11
12 **Abstract:** Inadequate sleep is a global health concern. Sleep is multidimensional and complex;
13 new multi-ingredient agents are needed. This study assessed the comparative effects of two mul-
14 ti-ingredient supplements on sleep relative to placebo. Adults (N=620) seeking better sleep were
15 randomly assigned to receive 1 of 3 study products (Sleep A, Sleep B or placebo) for 4 weeks. Both
16 active products contained federally legal hemp-derived cannabinoids, botanical oils, GABA and
17 L-theanine. Sleep disturbance was assessed at baseline and weekly using NIH's Patient-Reported
18 Outcomes Measurement Information System (PROMIS™) Sleep Disturbance SF 8A survey. Anxi-
19 ety, stress, pain, and well-being were assessed using validated measures at baseline and weekly.
20 A linear mixed-effects regression model was used to assess the change in health outcome score
21 between active product groups and the placebo. There was a significant difference in sleep dis-
22 turbance, anxiety, stress, and well-being between Sleep A and placebo. There was no significant
23 difference in any health parameter between Sleep B and placebo. Side effects were mild or moder-
24 ate. There were no significant differences in the frequency of side effects between the study groups.
25 A botanical blend containing a low concentration of THC improved sleep disturbance, anxiety,
26 stress, and well-being in healthy individuals that reported better sleep as a primary health concern.

27 **Keywords:** Sleep; botanical synergy; cannabinoids; health related quality of life; PROMIS

28

Citation: To be added by editorial staff during production. 29

Academic Editor: Firstname 30
Lastname

Received: date 31

Revised: date

Accepted: date 32

Published: date

 33

Copyright: © 2023 by the author. 34

Submitted for possible open access publication under the terms and 35

conditions of the Creative Commons

Attribution (CC BY) license 36

(<https://creativecommons.org/licenses/by/4.0/>)

4.0 International

1.Introduction

Inadequate sleep has become a global public health concern, leading to greater awareness of the negative impact from a lack of sleep. Inadequate sleep increases obesity and inflammation, impairs immune and antioxidant defenses, and negatively impacts mood [1,2]. Inadequate sleep is associated with heightened emotional reactivity, reduced attention, and impaired memory and cognitive function [3]. Individuals who are sleep deprived are less productive and report a lower overall quality of life [4]. It has been suggested that shorter sleep duration alters the gut microbiome. In turn, these changes in gut microbiome may drive increases in systemic inflammation associated with metabolic syndrome and many other lifestyle related conditions [5].

It is recommended that anyone suffering with sleep disturbances consult a health professional and consider a multidimensional assessment, recognizing that an intervention that targets sleep onset may not accurately address sleep latency. Furthermore, because sleep involves multiple mechanisms, it may be advantageous to consider a multi-ingredient therapeutic approach targeting a variety of pathways to support sleep. There are many treatments aimed at improving sleep, including behavioral management, lifestyle management, exercise, diet, pharmacological interventions, and dietary supplements [6]. Many individuals experience negative side effects from prescribed medications, and choose to seek alternate solutions, such as dietary supplements and plant-based alternatives [7].

Cannabinoids are a potential plant-based alternative to prescription products for improving sleep. The cannabis plant is composed of 120 different phytocannabinoids. Delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD) are perhaps the most widely known and researched, but others like CBN are growing in popularity [8,9]. Cannabinoids produce varying effects in the human body by interacting with the endocannabinoid system (ECS), which is located throughout the brain and the central and peripheral nervous system [8]. The ECS has been suggested to modulate the circadian sleep/wake cycle. Therefore, the role of cannabinoids on sleep modulation is supported by the role of the endocannabinoid system on circadian regulation [9]. A recent systematic review, including 14 preclinical and 12 clinical studies, concluded “there are promising signs in a number of therapeutic applications that warrant additional study and there is a clear need for intensification of high-quality research into the safety and efficacy of cannabinoid therapies for treating sleep disorders...”[10]. CBD is non-intoxicating and has been shown to be safe and well-tolerated in humans, even at very high doses (e.g., 1500 mg twice daily for six days or as an acute dose of 6000 mg [11]. Cannabinol (CBN) is a by-product of THC and is found in small amounts in the cannabis plant. CBN has gained consumer interest as an ingredient to benefit sleep [12,13]. However, research related to CBN and sleep is limited, and the majority of it dates back to the 1970s and 80s [14].

Other non-pharmacological alternatives have been investigated. For example, γ -aminobutyric acid (GABA) is a non-protein amino acid, well known for its role as an inhibitory neurotransmitter in the central nervous system, promoting relaxation and sleep [15,16]. Additionally, γ -Glutamylethylamine, also known as L-theanine, is a non-protein amino acid found in green tea, often used to improve sleep and modify stress. It is thought to increase expression of dopamine and serotonin in the brain by increasing GABA levels [17,18]. It has been suggested that these compounds provide synergistic benefits. In mice, GABA/L-theanine mixture (100/20 mg/kg) demonstrated a decrease in sleep latency (20.7 and 14.9%) and an increase in sleep duration (87.3 and 26.8%) compared to GABA or L-theanine alone [18].

Botanical essential oils are also gaining popularity for their effectiveness in improving sleep. Hops is an herbaceous perennial plant belonging to the class Magnoliopsida, subclass Hamamelididae, order Urticales, family Cannabaceae, genus *Humulus*. It has been known for centuries for its many health benefits, including its sedative effects [19]. Several studies support the sedative properties of hops oil [20,21].

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90

91 The sedative effect is thought to occur due to a degradation product,
92 2-methyl-3-buten-2-ol, that increases GABA [22]. Alone, the amount of any one botanical
93 is most likely too low to lead to any significant benefit, but it is believed that the synergy
94 with other phytochemicals produces the effect [23,24].

95 Another popular oil often used together with hops, is Valeriana L., a group of per-
96 ennial herbs belonging to the family Caprifoliaceae. It has been used for centuries around
97 the globe to improve sleep. The roots and rhizomes are most often used for medicinal
98 benefits. There are more than 200 species of Valeriana, with Valeriana officinalis L used
99 most often in US products. In mice, the essential oil was determined to be the active part
100 of the plant. The compounds within the oils could act synergistically on GABA receptors
101 to increase GABA release and inhibit uptake [25-27].


102 Though each of the botanicals discussed thus far has shown promise for improving
103 sleep, it is intriguing to consider the concept of synergy, especially because sleep is mul-
104 tidimensional and complex, thus warranting a multi-ingredient approach. The discussion
105 of botanical synergy is not new. In recent years, it has been commonly called “the en-
106 tourage effect” when discussed in reference to the potential therapeutic effects of the
107 synergy between phytocannabinoids and the many other compounds found in the can-
108 nabis plant [28]. Demonstrated by several review papers, the application of botanical
109 synergy extends beyond the cannabis plant to other botanicals [29,30]. It has been sug-
110 gested that synergy among the cannabinoid compounds may enhance the effectiveness of
111 THC, thus allowing a lower effective dose, minimizing the psychoactive effects of THC
112 while maintaining the benefits [31]. Whether compounds from other botanicals would
113 provide a similar synergistic effect is unknown.

114 The aim of this study was to assess the effects of two different softgel dietary sup-
115 plements, one with lower THC and higher levels of other botanicals (Sleep A), and one
116 with higher THC and lower levels of other botanicals (Sleep B), on sleep disturbance re-
117 lative to placebo.

118 2. Materials and Methods

119 This study, Radicle™ Rest, was a randomized, double-blind, placebo-controlled,
120 parallel group, virtual trial, designed to assess the effects of health and wellness products
121 on sleep, anxiety, stress, pain, and overall health-related quality of life. Participants were
122 not required to attend in-person visits. All data were collected via online surveys which
123 participants accessed via participant specific hyperlinks sent to them at scheduled times
124 through their preferred means of communication (email or SMS text). Participants were
125 recruited online from across the US through social media, Radicle Science’s electronic
126 mailing list, and a third-party consumer network with nationwide representation. Re-
127 cruitment emails containing links to the study screener were sent to those within the
128 Radicle Science mailing list and consumer network, while social media advertisements
129 led to a study landing page with a link to the study screener. Participants were eligible if
130 they were 21 years old or older, resided in the United States, expressed a desire for better
131 sleep, and ranked their desire for better sleep as a primary reason for taking a dietary
132 supplement. Individuals were excluded if they were pregnant or breastfeeding, or taking
133 medications that posed a health risk when used in conjunction with any of the study
134 product ingredients. Eligible individuals were directed to a secure online portal to pro-
135 vide informed consent. Participants indicated their consent electronically by signing the
136 informed consent form and were sent a digital copy of the electronic consent. Eligible
137 individuals were advised to consult with their healthcare provider before participating if
138 they had a diagnosed medical condition, were on any prescription medication or sup-
139 plements, or had any upcoming medical procedures planned. Immediately following
140 informed consent, participants completed an intake survey which collected basic demo-
141 graphic information, health behaviors, and experienced sleep quality.

142 Recruits who consented to participate and completed intake were randomized to
 143 one of three study arms (see below for details on randomization): Sleep A, Sleep B, or
 144 Placebo (Figure 1).
 145



146
 147 **Figure 1.** Study Flow Diagram. Eligible participants were enrolled in the study and ran-
 148 domized into one of three groups: Sleep A, Sleep B, or placebo. We collected baseline
 149 clinical measures before participants started using their study product. Participants used
 150 study product for 4 weeks total. Clinical and other measures were collected at the end
 151 of each week as well as 1 week post study product use.
 152

153 Participants were sent a 4-week supply of their study product in the mail, along with
 154 the product insert, detailing instructions for study participation. All study products were
 155 provided by the partnering manufacturer and analyzed at an independent laboratory to
 156 ensure active ingredient identification, safety, and potency. Participants were instructed
 157 to take one softgel 30 minutes before bedtime, and informed that they could escalate to a
 158 maximum of 4 softgels per day as needed throughout the study duration. Participants
 159 were directed to wait 5 days before increasing the number of softgels taken. The study
 160 product formulations are proprietary to the manufacturer but both Sleep A and B for-
 161 mulations contained the same amount of CBD, CBN, and L-theanine; Sleep A formula
 162 contained lower amounts of THC and higher amounts of GABA, hops oil and valerian oil
 163 relative to the Sleep B formula. The study was double-blind; neither the participants nor
 164 those who collected and analyzed the data were aware of the product participants re-
 165 ceived until the conclusion of the study. The study was conducted from Oct 2022 to Dec
 166 2022

167 For 5 weeks following the study initiation and baseline (4 weeks taking the study
 168 product and 1 week after finishing the study product), participants were asked to com-
 169 plete online surveys, which they accessed via unique hyperlinks sent at scheduled times
 170 via email or text. During the baseline week, participants completed health outcome as-
 171 sessments of their sleep, feelings of anxiety, stress, pain, and overall well-being, using
 172 validated, patient reported outcome measures (Table 1).
 173

174 Table 1. Validated measures for key outcomes used in Radicle Rest study.
 175

Measure	Description	Scoring interpretation	How was this collected?
PROMIS Sleep Dis- turbance 8a	8-item measure assessing sleep disturb- ance (sleep quality) in the past 7 days	Scoring from 8 to 40, with higher scores translating to greater sleep disturbance	All participants received this measure within their weekly health surveys
PROMIS Anxiety 4a	4-item measure assessing frequency of anxiety symptoms in the past 7 days	Scoring from 4 to 20, with higher scores translating to greater anxiety	Participants who endorsed anxiety symptoms received this measure in their weekly health surveys.
PROMIS Stress 4a	4-item measure assessing frequency of	Scoring from 4 to 20, with	Participants who endorsed stress

	stress symptoms in the past 7 days	higher scores translating to greater stress	symptoms received this measure in their weekly health surveys.
PEG (Pain, Enjoyment, General Activity) scale	3-item measure assessing pain intensity and interference in the past 7 days	Scoring from 0 to 10, with higher scores translating to greater pain	Participants who endorsed pain symptoms received this measure in their weekly health surveys.
World Health Organization (WHO)-5 Well-being index	5-item measure assessing feelings of well-being in the past 7 days	Scoring from 0 to 25, with higher scores translating to greater well-being	All participants received this measure within their weekly health surveys

176
177
178
179
180
181
182
183
184
185
186
187

188
189
190
191
192
193

194
195
196
197
198
199
200
201
202
203
204
205

206
207
208
209
210
211
212
213
214

Throughout the study duration, participants received a health survey asking them to report their study product usage for the week and health outcome assessments for their sleep disturbance, feelings of anxiety, stress, pain and overall well-being from the past week using the same validated health measures used at baseline. In every study survey, following receipt of their product, participants were also prompted to report any side effects, and were encouraged to contact the research team directly if they experienced side effects at any point.

Sterling Independent Review Board (SIRB) approved the study [10147]. The master protocol Radicle Rest™ was registered on ClinicalTrials.gov [Identifier: NCT05511818]. It should be noted that the protocol registered is not this specific study but rather is the templated study protocol utilized for all Radicle Rest studies.

2.1. Randomization

Participants were randomly assigned to one of the three study product arms, with an equal chance of being assigned to each group (1:1:1 ratio). Prior to randomization, participants were stratified by their assigned sex at birth (male, female) then randomized to one of the study arms using the randomizer with evenly presented elements in the Qualtrics® XM platform.

2.2. Outcomes

Radicle™ Rest is a templated trial protocol incorporating validated assessments which has received overall IRB approval that is then applied to each individual study. The study design and assessments used do not change from study to study, only the actives and placebos change. The primary outcomes were change in the PROMIS™ Sleep Disturbance 8A scale [32] as well as the odds of achieving a minimal clinically important difference (MCID). MCID was defined as a reduction which is greater than or equal to one-half the standard deviation of the baseline score [33]. The MCID standard deviation criterion was calculated by study arm. Secondary outcomes included changes in anxiety, stress, pain, and overall wellbeing. Secondary outcomes were assessed using PROMIS™ Anxiety 4a, PROMIS™ Stress 4a, PEG (Pain, Enjoyment, General Activity), and World Health Organization (WHO)-5 Well-being index.

2.3. Safety

The frequency of spontaneously reported side effects and their severity were assessed. Severity was determined based on reported utilization of medical services in response to the side effects according to the following grading schema based on the Common Terminology Criteria for Adverse Events (CTCAE; v5.0 USDHHS): mild: no intervention (medication or medical advice) needed; moderate: a medication was taken due to the side effect or a participant sought medical advice from their HCP, urgent clinic or ED; severe: the side effect was medically significant but not life-threatening and/or the participant was admitted to the hospital for care and attention; life threatening: immedi-

215 ate medical intervention required and the participant was hospitalized, placed in the
216 intensive care unit due the side effect, and/or suffered long-lasting negative effects as a
217 result of the side effect.

218 2.4. Covariates

219 Prior to analysis, we collapsed three demographic variables, including race, educa-
220 tion, and ethnicity. Race was recoded as white (including participants who identified as
221 white), non-white (including participants who identified as Black, Multi-racial, Asian,
222 Unknown, Prefer not to say, Some other race, or American Indian or Alaska Native), and
223 Native Hawaiian or Pacific Islander (including participants who identified as Native
224 Hawaiian or Pacific Islander). Education was recoded as college degree (including par-
225 ticipants who have a bachelor's or associate degree, and masters or professional degree),
226 and No college degree (including participants who selected prefer not to say, less than
227 high school, trade/technical/vocational degree, high school diploma no college, and some
228 college no degree). Ethnicity was recoded to Hispanic (including participants who se-
229 lected Yes) and Non-Hispanic (including participants who selected no, or prefer not to
230 say). We adjusted for baseline demographics, including age, recoded race, recoded eth-
231 nicity, recoded education level, sex assigned at birth (male, female), and body mass index
232 (BMI; calculated through self-reported height and weight).

233 2.5. Power analysis

234 A power analysis was conducted to ensure sufficient power to detect a significant
235 difference in the change in the PROMIS™ Sleep Disturbance 8A scale for each study
236 product arm relative to placebo. A sample size of 190 for each study group would yield
237 90% power to find a difference in mean change between each study product arm versus
238 the placebo arm at a two-sided p value of 0.05 corrected for multiple comparisons
239 (Bonferroni). Recruiting up to 300 participants per study arm would allow us to maintain
240 adequate sample size under anticipated attrition levels (45%).

241 2.6. Statistical analysis

242 A linear, mixed-effects regression model was used to assess the differences in the
243 change in the variables of interest between each active product arm versus placebo. The
244 parameter "na.action = na.omit" was set for each model, meaning that participants were
245 excluded only from those models for which they did not have available data. All models
246 were fit using an unstructured covariance matrix with a random-intercept at the indi-
247 vidual level, and a random-slope and intercept at the study week level. The models
248 tested the difference in the interaction between product arm and study week for active
249 arm versus placebo, controlling for sex, age, race, ethnicity, and BMI. Post hoc
250 Bonferroni-adjusted pairwise comparisons were used to assess the differences in the
251 odds of achieving a MCID for sleep between each active product arm placebo, controlling
252 for sex, age, race, ethnicity, education, and BMI.

253 2.7. Software

254 The Python programming language, version 3.95 (packages: pandas, version 1.4.3,
255 and numpy, version 1.20.2) were used for data processing. R, version 4.2.3 (packages:
256 nlme, version 3.1-162, marginal effects, version 0.11.1, and tidyverse, version 2.0.0) was
257 used to conduct the statistical analyses, and package table one version 0.13.2 was used to
258 create table one.

259 3. Results

260 3.1. Participants

261 Subsubsection The study population reflects well the population of US consumers that
 262 elect to purchase health and wellness supplements. At baseline, 90% of participants
 263 reported that they suffered from stress and 76% reported that they suffered from sleep
 264 disturbances most (63.6% reported mild or moderate sleep disturbances). In this study,
 265 66% of participants were female, 34% were male and 80% identified their race as white.
 266 After stratification, 206 participants were randomly assigned to Sleep A, 207 to Sleep B,
 267 and 207 to Placebo. The groups did not significantly differ on any demographic or out-
 268 comes variables at baseline (Table 2).

269 **Table 2.** Participant sample summary at baseline.

Variable	Placebo	Arm 1	Arm 2	t / χ^2 p-value
	Mean (SD)/N (%)	Mean (SD)/N (%)	Mean (SD)/N (%)	
N	207	206	207	
Age	44.51 (11.08)	45.08 (11.00)	45.35 (10.86)	0.73
Race				0.307
White	177 (85.5)	162 (78.6)	167 (80.7)	
Non-White	29 (14.0)	44 (21.4)	39 (18.8)	
Native Hawaiian or Pacific Islander	1 (0.5)	0 (0.0)	1 (0.5)	
Education: No College Degree	96 (46.4)	116 (56.3)	97 (46.9)	0.075
Sex At Birth: Male	71 (34.3)	71 (34.5)	71 (34.3)	0.999
Hispanic, LatinX, or Spanish origin: Yes	19 (9.2)	20 (9.7)	17 (8.2)	0.865
BMI	29.27 (7.95)	30.59 (8.10)	30.17 (8.00)	0.233
PROMIS Sleep Disturbance 8A	28.82 (6.22)	29.85 (6.59)	29.65 (6.39)	0.22
PROMIS Anxiety 4A	10.46 (3.47)	11.02 (3.60)	11.06 (3.35)	0.145
PROMIS Stress 4A	12.81 (3.42)	13.36 (3.76)	13.39 (3.55)	0.176
Pain, Enjoyment, General Activity Scale	5.60 (2.14)	5.87 (2.30)	5.68 (2.10)	0.618


270

271

3.2. Sleep Quality

272 The interaction between Study Week and Sleep A (Arm 1) showed a significant negative
 273 association with sleep disturbance ($\beta = -0.639$, $p = 0.0027$). This indicates that the effect of
 274 Study Week on sleep disturbance differed between the treatment groups, with partici-
 275 pants in Sleep A (Arm 1) experiencing a greater reduction in sleep disturbance over time
 276 compared to the placebo group. Education demonstrated a significant positive associa-
 277 tion with sleep disturbance ($\beta = 1.846$, $p < 0.0001$), suggesting that individuals without a
 278 college degree reported higher levels of sleep disturbance. BMI exhibited a significant
 279 positive association with sleep disturbance ($\beta = 0.070$, $p = 0.0163$), indicating that higher
 280 BMI was associated with higher levels of sleep disturbance (Figure 2, Table 3). We did not
 281 observe any significant differences in the likelihood of achieving a minimum clinically
 282 important difference (MCID) in between Sleep A (estimate = 1.33, 95% CI[0.85, 1.81], $p =$
 283 0.242) or or Sleep B (estimate = 1.23, 95% CI[0.79, 1.67], $p = 0.477$) and placebo (42.2 %).
 284 MCID is defined as a change of one half the standard deviation of the baseline score.

285
286
287
288
289
290
291
292
293
294



295 **Figure 2.** Interaction between Treatment and Week on PROMIS Sleep Disturbance 8a score. The plot il-
296 lustrates the interaction between treatment (Sleep A; Arm 1 and Sleep B; Arm 2) and week on the sleep
297 disturbance scale, based on a linear mixed-effects model. The x-axis represents the weeks of the study,
298 while the y-axis represents the outcome scale. The lines represent the trajectories of sleep disturbance
299 for each treatment arm over time. The plot highlights the nature of treatment effects on sleep quality,
300 captured by the linear mixed-effects model, allowing for the incorporation of random effects and accounting
301 for within-subject correlations.

302
303
304
305
306
307
308
309
310

Table 3. Significant Factors Associated with Sleep Disturbance: Results from a Linear Mixed Effects Regression Model. Summary of significant variables and their associations with sleep disturbance based on a linear mixed-effects regression model. The model was used to assess the differences in the change in the variables of interest between each active product arm versus placebo. The table presents the beta coefficients (β), standard errors (Std.Error), degrees of freedom (DF), t-values, and p-values for each variable. Higher values indicate a stronger positive association with sleep disturbance, while lower values indicate a stronger negative association.


	Value	Std.Error	DF	t-value	p-value
(Intercept)	24.725	1.367	1238	18.089	<0.001
Education	1.846	0.477	610	3.872	<0.001
Sex at Birth	-0.075	0.492	610	-0.153	0.879
Age	-0.018	0.022	610	-0.822	0.411
Race: Non-white	-0.933	0.615	610	-1.517	0.130
Race: Native Hawaiian or Pacific Islander	3.028	3.833	610	0.790	0.430
BMI	0.070	0.029	610	2.408	0.016
Hispanic, LatinX, or Spanish origin	0.152	0.830	610	0.184	0.854
Study Week	-1.339	0.150	1238	-8.919	<0.001
TreatSleep A (Arm 1)	0.424	0.592	610	0.715	0.475

TreatSleep B (Arm 2)	0.458	0.586	610	0.781	0.435
Study Week:TreatSleep A (Arm 1)	-0.639	0.212	1238	-3.010	0.003
Study Week:TreatSleep B (Arm 2)	-0.236	0.208	1238	-1.133	0.257

311
312
313
314
315
316
317
318
319
320
321

3.3. Sleep Quality

The analysis revealed several significant associations with anxiety. First, there was a significant negative interaction between Study Week and Sleep A (Arm 1) ($\beta = -0.258$, $p = 0.041$), indicating that as the study progressed, participants using Sleep A were more likely to experience a decrease in anxiety compared to participants using placebo (Figure 3, Table 4). Additionally, education showed a significant positive association with anxiety ($\beta = 0.744$, $p = 0.005$), suggesting that individuals with a higher level of education experienced higher levels of anxiety. Lastly, age demonstrated a significant negative association with anxiety ($\beta = -0.035$, $p = 0.005$), indicating that as age increased, anxiety levels tended to decrease.



322
323
324
325
326
327
328
329
330
331
332
333
334

Figure 3. Interaction between Treatment and Week on PROMIS Anxiety 4a score. The plot illustrates the interaction between treatment (Sleep A; Arm 1 and Sleep B; Arm 2) and week on the anxiety scale, based on a linear mixed-effects model. The x-axis represents the weeks of the study, while the y-axis represents the outcome scale. The lines represent the trajectories of anxiety for each treatment arm over time. The plot highlights the nature of treatment effects on anxiety as captured by the linear mixed-effects model, allowing for the incorporation of random effects and accounting for within-subject correlations.

Table 4. Significant Factors Associated with Anxiety: Results from a Linear Mixed Effects Regression Model. Summary of significant variables and their associations with anxiety based on a linear mixed-effects regression model. The model was used to assess the differences in the change in the variables of interest between each active product arm versus placebo. The table presents the beta coefficients (β), standard er-


335 rors (Std.Error), degrees of freedom (DF), t-values, and p-values for each variable. Higher values indicate a
 336 stronger positive association with anxiety, while lower values indicate a stronger negative association.

	Value	Std.Error	DF	t-value	p-value
(Intercept)	11.007	0.764	773	14.415	<0.001
Education: No College Degree [Ref: College Degree]	0.744	0.266	610	2.795	0.005
Sex at Birth: Male [Ref: Female]	-0.398	0.276	610	-1.439	0.151
Age	-0.035	0.012	610	-2.855	0.005
Race: No-white [Ref: white]	-0.027	0.345	610	-0.078	0.938
Race: Native Hawaiian or Pacific Islander [Ref: white]	0.667	2.258	610	0.295	0.768
BMI	0.021	0.016	610	1.264	0.207
Hispanic, LatinX, or Spanish origin: Yes [Ref: No]	0.196	0.452	610	0.434	0.665
Study Week	-0.445	0.087	773	-5.126	<0.001
Sleep A (Arm 1)	0.388	0.329	610	1.179	0.239
Sleep B (Arm 2)	0.577	0.326	610	1.769	0.078
Study Week: Sleep A (Arm 1)	-0.259	0.127	773	-2.044	0.041
Study Week: Sleep B (Arm 2)	-0.066	0.123	773	-0.537	0.592

337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350

3.4. Anxiety

The interaction between Study Week and Sleep A (Arm 1) showed a significant negative association with stress ($\beta = -0.360$, $p = 0.004$). This indicates that the effect of Study Week on stress levels differed between the treatment groups, with participants in Sleep A (Arm 1) showing a larger decrease in stress over time compared to the placebo group (Figure 4, Table 5). Additionally, Sex demonstrated a significant negative association with stress ($\beta = -0.666$, $p = 0.019$), suggesting that males reported higher levels of stress compared to females. Age showed a significant negative association with stress ($\beta = -0.065$, $p < 0.001$), indicating that older participants reported lower levels of stress. Furthermore, BMI exhibited a significant positive association with stress ($\beta = 0.033$, $p = 0.049$), indicating that higher BMI was associated with higher stress levels.



351
 352

Figure 4. Interaction between Treatment and Week on PROMIS Stress 4a score. The plot illustrates the interaction between treatment (Sleep A; Arm 1 and Sleep B; Arm 2) and week on the stress scale, based on a linear mixed-effects model. The x-axis represents the weeks of the study, while the y-axis represents the outcome scale. The lines represent the trajectories of stress for each treatment arm over time. The plot highlights the nature of treatment effects on stress as captured by the linear mixed-effects model, allowing for the incorporation of random effects and accounting for within-subject correlations.

Table 5. Significant Factors Associated with Stress: Results from a Linear Mixed Effects Regression Model. Summary of significant variables and their associations with stress based on a linear mixed-effects regression model. The model was used to assess the differences in the change in the variables of interest between each active product arm versus placebo. The table presents the beta coefficients (β), standard errors (Std.Error), degrees of freedom (DF), t-values, and p-values for each variable. Higher values indicate a stronger positive association with stress, while lower values indicate a stronger negative association.

	Value	Std.Error	DF	t-value	p-value
(Intercept)	14.746	0.782	835	18.856	<0.001
Education: No College Degree [Ref: College Degree]	0.435	0.272	610	1.597	0.111
Sex at Birth: Male [Ref: Female]	-0.666	0.283	610	-2.353	0.019
Age	-0.065	0.012	610	-5.239	<0.001
Race: Non-white [Ref: white]	-0.287	0.352	610	-0.814	0.416
Race: Native Hawaiian or Pacific Islander [Ref: white]	-0.108	2.331	610	-0.046	0.963
BMI	0.033	0.017	610	1.971	0.049
Hispanic, LatinX, or Spanish origin: Yes [Ref: No]	-0.107	0.471	610	-0.228	0.820
Study Week	-0.521	0.088	835	-5.913	<0.001
Sleep A (Arm 1)	0.202	0.334	610	0.605	0.545
Sleep B (Arm 2)	0.501	0.332	610	1.507	0.132
Study Week: Sleep A (Arm 1)	-0.360	0.126	835	-2.864	0.004
Study Week: Sleep B (Arm 2)	-0.047	0.125	835	-0.372	0.710

3.5. Pain

Our primary analyses revealed no significant differences in the rate of mean PEG (Pain, Enjoyment, General Activity) score change between Sleep A and placebo ($\beta = -0.024$, $p = 0.788$), or between Sleep B and placebo ($\beta = 0.032$, $p = 0.713$), see Table 6. However, age showed a significant positive association with pain ($\beta = 0.024$, $p = 0.019$), indicating that as age increased, participants reported higher levels of pain. Education also demonstrated a significant positive association with pain ($\beta = 0.706$, $p = 0.0023$), suggesting that individuals with a higher level of education experienced higher levels of pain. Additionally, Study Week showed a significant negative association with pain ($\beta = -0.307$, $p < 0.001$), indicating that as the study progressed, participants reported lower levels of pain.

Table 6. Significant Factors Associated with Pain: Results from a Linear Mixed Effects Regression Model. Summary of significant variables and their associations with pain based on a linear mixed-effects regression model. The model was used to assess the differences in the change in the variables of interest between each active product arm versus placebo. The table presents the beta coefficients (β), standard errors (Std.Error), degrees of freedom (DF), t-values, and p-values for each variable. Higher values indicate a stronger positive association with pain, while lower values indicate a stronger negative association.


	Value	Std.Error	DF	t-value	p-value
(Intercept)	3.078	0.647	689	4.760	<0.001
Education: No College Degree [Ref: College Degree]	0.706	0.230	346	3.076	0.002

Sex at Birth: Male [Ref: Female]	-0.016	0.241	346	-0.067	0.946
Age	0.024	0.010	346	2.355	0.019
Race: Non-white [Ref: white]	0.014	0.297	346	0.046	0.964
BMI	0.030	0.013	346	2.304	0.022
Hispanic, LatinX, or Spanish origin: Yes [Ref: No]	0.216	0.458	346	0.471	0.638
Study Week	-0.307	0.063	689	-4.875	<0.001
Sleep A (Arm 1)	-0.073	0.273	346	-0.267	0.790
Sleep B (Arm 2)	-0.155	0.274	346	-0.566	0.572
Study Week: Sleep A (Arm 1)	-0.024	0.087	689	-0.270	0.788
Study Week: Sleep B (Arm 2)	0.032	0.088	689	0.368	0.713

383
384
385
386
387
388
389
390
391
392
393

3.6. Overall well-being

The interaction between Study Week and Sleep A (Arm 1) showed a significant positive association with wellbeing ($\beta = 0.318$, $p = 0.0346$). This indicates that the effect of Study Week on overall wellbeing differed between the treatment groups, with participants in Sleep A (Arm 1) experiencing a greater improvement in wellbeing over time compared to the placebo group. Education demonstrated a significant negative association with wellbeing ($\beta = -1.559$, $p < 0.001$), suggesting that individuals without a college degree reported lower levels of overall wellbeing. BMI exhibited a significant negative association with wellbeing ($\beta = -0.060$, $p = 0.0061$), indicating that higher BMI was associated with lower levels of wellbeing (Figure 5, Table 7).



394
395
396
397
398
399
400
401
402
403
404
405

Figure 5. Interaction between Treatment and Week on World Health Organization (WHO)-5 Well-being index. The plot illustrates the interaction between treatment (Sleep A; Arm 1 and Sleep B; Arm 2) and week on the wellbeing scale, based on a linear mixed-effects model. The x-axis represents the weeks of the study, while the y-axis represents the outcome scale. The lines represent the trajectories of wellbeing for each treatment arm over time. The plot highlights the nature of treatment effects on wellbeing as captured by the linear mixed-effects model, allowing for the incorporation of random effects and accounting for within-subject correlations.

Table 7. Significant Factors Associated with Overall Well-Being: Results from a Linear Mixed Effects Regression Model. Summary of significant variables and their associations with overall well-being based on a linear mixed-effects regression model. The model was used to assess the differences in the change in the variables of interest between each active product arm versus placebo. The table presents the beta coefficients (β), standard


406 errors (Std.Error), degrees of freedom (DF), t-values, and p-values for each variable. Higher values indicate a
 407 stronger positive association with overall well-being, while lower values indicate a stronger negative association.

	Value	Std.Error	DF	t-value	p-value
(Intercept)	11.251	1.020	1238	11.031	<0.001
Education: No College Degree [Ref: College Degree]	-1.559	0.356	610	-4.383	<0.001
Sex at Birth: Male [Ref: Female]	0.315	0.368	610	0.856	0.392
Age	0.015	0.016	610	0.898	0.369
Race: Non-white [Ref: white]	0.781	0.458	610	1.706	0.089
Race: Native Hawaiian or Pacific Islander [Ref: white]	1.657	2.918	610	0.568	0.570
BMI	-0.060	0.022	610	-2.752	<0.001
Hispanic, LatinX, or Spanish origin: Yes [Ref: No]	0.266	0.616	610	0.432	0.666
Study Week	0.672	0.106	1238	6.308	<0.001
Sleep A (Arm 1)	0.422	0.431	610	0.980	0.327
Sleep B (Arm 2)	0.084	0.427	610	0.196	0.844
Study Week: Sleep A (Arm 1)	0.318	0.151	1238	2.116	<0.001
Study Week: Sleep B (Arm 2)	-0.005	0.148	1238	-0.037	0.971

408
 409
 410
 411
 412
 413
 414

3.3. Side Effects

Side effects were slightly more common among the active arms (Arm 1 and Arm 2, ($\chi^2(2) = 5.64, p = 0.059$)), predominantly grogginess and drowsiness and mostly mild; none was considered serious or required use of emergency or non-emergency healthcare services (Figure 6).



415
 416 **Figure 6.** Comparison of side effects between active arms (Sleep A; Arm 1 and Sleep B;
 417 Arm 2) and placebo. This figure displays the occurrence of side effects in the active arms
 418 (Sleep A; Arm 1 and Sleep B; Arm 2) compared to the placebo group. Participants with
 419 sleep disturbance received Sleep A (Arm 1), Sleep B (Arm 2), or placebo for 4 weeks. Side
 420 effects, primarily grogginess and drowsiness, were slightly more common in the active

421 arms but were mild and non-serious, requiring no emergency or non-emergency
422 healthcare services.

423 4. Discussion

424 We presented a randomized, double-blinded, placebo-controlled trial to evaluate the
425 effectiveness and safety of two orally ingested softgel dietary supplements, Sleep A and
426 Sleep B, compared to a placebo over four weeks of treatment. We observed a significant
427 difference in effect on four health outcomes (sleep disturbance, anxiety, stress, and over-
428 all well-being) between Sleep A formula and placebo control. We observed no significant
429 difference in effect on any health outcomes between Sleep B formula and placebo control.
430 Importantly, both supplements exhibited favorable safety profiles, as all side effects were
431 mild or moderate and there were no significant differences in the frequency of reported
432 side effects between the active and placebo arms.

433 This study is among the first to investigate the effectiveness and safety of supple-
434 ments that aim to enhance sleep and overall health in a large participant sample. These
435 supplements were specifically designed to harness the potential synergistic effects of
436 botanical ingredients that have demonstrated favorable outcomes in promoting better
437 sleep. Our primary analyses indicate that over the course of four weeks using the study
438 product, the Sleep A group experienced a significantly greater reduction in sleep dis-
439 turbance compared to the placebo group. Additionally, participants in the Sleep A group
440 also showed significantly greater improvements in anxiety, stress, and overall well-being
441 compared to those in the placebo group. These results are expected, given the intricate
442 connections between sleep, anxiety, stress, and overall well-being [34].

443 Interestingly, we observed no significant differences in any of the health outcomes
444 between Sleep B and placebo. It is important to note that both Sleep A and B formulas
445 contained the same amount of CBD, CBN, and L-Theanine, while Sleep formula A con-
446 tained a lower amount of THC and higher amounts of GABA, hops oil, and valerian oil
447 than the Sleep B formula. Since the current study did not employ a factorial design to
448 examine the individual effects of all ingredients, as well as their potential interactions, we
449 are unable to determine the main driver(s) between the different impacts Sleep A and
450 Sleep B had on behavioral outcomes. We put forward a hypothesis regarding the poten-
451 tial reasons for the superior performance of Sleep A in reducing sleep disturbances
452 compared to Sleep B. There are two primary factors that we believe contribute to this
453 outcome. Firstly, Sleep A contains a lower amount of THC compared to Sleep B. One
454 study found that those participants who use cannabis multiple times a week for its
455 sleeping effects prefer strains with lower amounts of THC, suggesting that the strains
456 with lower THC may be more effective at promoting sleep [35]. Secondly, Sleep A con-
457 tains higher levels of three specific ingredients: GABA, hops oil, and valerian oil. These
458 ingredients are known to function as positive modulators of GABA, a neurotransmitter
459 associated with promoting sleep and inducing mild sedation [23,36]. Therefore, it is
460 plausible that the presence of these ingredients in Sleep A contributes to its effectiveness
461 in improving sleep quality.

462 The data obtained in the present study are consistent with previous findings that a
463 combination of cannabinoids could improve sleep. For example, a randomized, con-
464 trolled crossover trial administering a combination product, containing THC 20 mg/mL,
465 CBN 2 mg/mL, CBD 1 mg/mL, and naturally occurring terpenes (extracted from the
466 cannabis plant), in pharmaceutical grade sunflower oil, for 2 weeks, demonstrated an
467 improvement in sleep quality in subjects with insomnia when compared to placebo [13].
468 Similarly, subjects receiving a tablet containing 10 mg THC and 5 mg CBN nightly experi-
469 enced significantly improved sleep quality and slept significantly longer, with a 5% in-
470 crease in sleep duration [12]. We recently published the results of a similar sleep study on
471 1793 adults [37]. Participants were randomly assigned to take 1 of 6 products, containing
472 either 15 mg CBD or 5 mg melatonin, alone or in combination with minor cannabinoids,
473 including CBN. Most participants (56% to 75%) across all formulations experienced a

474 clinically important improvement in their sleep quality though not statistically better
475 than the active control group that took 5 mg of melatonin alone.

476 This study was intended to approximate the “real world” effectiveness of the study
477 products by administering them to a broad population that used the products in a man-
478 ner and setting similar to that of actual consumers. Unlike conventional clinical trials,
479 which often have restrictive eligibility criteria and rigorous monitoring, the data in
480 question may exhibit higher levels of missingness and heterogeneity. Nonetheless, con-
481 ventional clinical trials involving natural products frequently suffer from limited sample
482 sizes and lack external validity, as the participants' characteristics and behaviors may not
483 accurately represent those of real-world users. Consequently, studies like this try to re-
484 flect the real-world effects of such products and possess distinct value in their capacity to
485 provide evidence for regulatory and clinical decision-making and additional clinical trial
486 design [38].

487 Whether or not the results of our study reflect botanical synergy, meaning that the
488 higher levels of the hops, valerian, and GABA allowed for the lower level of THC to be
489 effective, was not directly investigated in this study. However, it poses interesting ques-
490 tions and warrants further investigation.

491 This study has multiple limitations. First, approximately 26% of participants did not
492 complete any follow-up surveys. However, the overall attrition level was still below our
493 anticipated attrition (45%) and the study remained adequately powered to detect signif-
494 icant sleep changes. Furthermore, because the products used in this study were combi-
495 natorial, we are unable to pinpoint the exact drivers of the observed changes.

496 Considering the complex combinations of products examined in this study, further
497 investigations are warranted to identify the specific active ingredient(s) responsible for
498 the observed significant effects. To achieve this, a rigorous study employing a factorial
499 design with multiple arms would be beneficial. This design would systematically vary
500 the ingredients in different combinations, allowing for the examination of both their in-
501 dividual effects and potential interactions on behavioral outcomes. Such an approach
502 would enhance our understanding of the precise drivers behind the observed effects.

503 5. Conclusions

504 In this randomized, double-blind, placebo-controlled trial to evaluate the effects of
505 two formulations of sleep softgels relative to placebo, we observed that a botanical blend
506 containing lower amounts of THC and higher amounts of GABA, hops oil, and valerian
507 oil significantly improved sleep quality, anxiety, stress, and overall well-being in healthy
508 individuals with a desire for better sleep. We observed no significant difference in ef-
509 fect on any health outcome (sleep quality, anxiety, stress, pain, or overall well-being)
510 between a botanical blend containing higher amounts of THC, and lower amounts of
511 GABA, hops oil, and valerian oil and the placebo control. The active products demon-
512 strated a favorable safety profile; all side effects were mild or moderate, and there were
513 no significant differences in the frequency of reported side effects between the active
514 arms and placebo.

516 **Author Contributions:** Conceptualization and Methodology, J. Chen and E. Pauli. Data curation
517 and formal analysis, C. Bryant.; writing—original draft preparation, A. Kolobaric and S.Hewlings.;
518 writing—review and editing, all authors. All authors have read and agreed to the published ver-
519 sion of the manuscript.”

520 **Funding:** “This research was funded by MDbio - The Doctors Brand™

521 **Institutional Review Board Statement:** The study was conducted in accordance with the Declara-
522 tion of Helsinki, and approved by Sterling Independent Review Board (SIRB) [10147]. The master
523 protocol Radicle Rest™ was registered on ClinicalTrials.gov [Identifier: NCT05511818]. It should be
524 noted that the protocol registered is not this specific study but rather is the templated study pro-
525 tocol utilized for all Radicle Rest studies.

526 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the
527 study.

528
529 **Data Availability Statement:** The data presented in this study are available on request from the
530 corresponding author. The data are not publicly available.

531 **Acknowledgments:** The authors would like to express our deepest gratitude to the participant
532 volunteers in this study without whom this study would not have been possible. We
533 acknowledge and appreciate the hard work of the Radicle Science study operations team and
534 MDBio - The Doctors Brand™ for the product formulas studied.

535 **Conflicts of Interest:** A. Kolobaric, S. Hewlings, J. Chen, E. Pauli are employed by Radicle Science,
536 the company who conducted the study. The funders had no role in the design of the study; in the
537 collection, analyses, or interpretation of data; in the writing of the manuscript.

538 References

- 539
- 540 1. Altman, N.G.; Izci-Balserak, B.; Schopfer, E.; Jackson, N.; Rattanaumpawan, P.; Gehrman, P.R.; Patel, N.P.; Grandner, M.A.
541 Sleep duration versus sleep insufficiency as predictors of cardiometabolic health outcomes. *Sleep medicine* **2012**, *13*,
542 1261-1270, doi:10.1016/j.sleep.2012.08.005.
 - 543 2. Golem, D.L.; Martin-Biggers, J.T.; Koenings, M.M.; Davis, K.F.; Byrd-Bredbenner, C. An integrative review of sleep for
544 nutrition professionals. *Advances in nutrition (Bethesda, Md.)* **2014**, *5*, 742-759, doi:10.3945/an.114.006809.
 - 545 3. McCoy, J.G.; Strecker, R.E. The cognitive cost of sleep lost. *Neurobiology of learning and memory* **2011**, *96*, 564-582,
546 doi:10.1016/j.nlm.2011.07.004.
 - 547 4. Institute of Medicine Committee on Sleep, M.; Research. The National Academies Collection: Reports funded by National
548 Institutes of Health. In *Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem*, Colten, H.R., Altevogt, B.M.,
549 Eds.; National Academies Press (US) Copyright © 2006, National Academy of Sciences.: Washington (DC), 2006.
 - 550 5. Reynolds, A.C.; Paterson, J.L.; Ferguson, S.A.; Stanley, D.; Wright, K.P., Jr.; Dawson, D. The shift work and health research
551 agenda: Considering changes in gut microbiota as a pathway linking shift work, sleep loss and circadian misalignment,
552 and metabolic disease. *Sleep medicine reviews* **2017**, *34*, 3-9, doi:10.1016/j.smrv.2016.06.009.
 - 553 6. Doherty, R.; Madigan, S.; Warrington, G.; Ellis, J. Sleep and Nutrition Interactions: Implications for Athletes. *Nutrients*
554 **2019**, *11*, doi:10.3390/nu11040822.
 - 555 7. Verma, K.; Singh, D.; Srivastava, A. The Impact of Complementary and Alternative Medicine on Insomnia: A Systematic
556 Review. *Cureus* **2022**, *14*, e28425, doi:10.7759/cureus.28425.
 - 557 8. Babson, K.A.; Sottile, J.; Morabito, D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. *Current psychiatry*
558 *reports* **2017**, *19*, 23, doi:10.1007/s11920-017-0775-9.
 - 559 9. Tham, M.; Yilmaz, O.; Alaverdashvili, M.; Kelly, M.E.M.; Denovan-Wright, E.M.; Laprairie, R.B. Allosteric and orthosteric
560 pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. *British*
561 *journal of pharmacology* **2019**, *176*, 1455-1469, doi:10.1111/bph.14440.
 - 562 10. Suraev, A.S.; Marshall, N.S.; Vandrey, R.; McCartney, D.; Benson, M.J.; McGregor, I.S.; Grunstein, R.R.; Hoyos, C.M.
563 Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. *Sleep*
564 *medicine reviews* **2020**, *53*, 101339, doi:10.1016/j.smrv.2020.101339.
 - 565 11. Taylor, L.; Gidal, B.; Blakey, G.; Tayo, B.; Morrison, G. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single
566 Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified
567 Cannabidiol in Healthy Subjects. *CNS drugs* **2018**, *32*, 1053-1067, doi:10.1007/s40263-018-0578-5.

- 568 12. Gannon, W.; Bronfein, W.; Jackson, D.; Holshouser, K.; Artman, B.E.; Schestepol, M.; Treacy, D.J.; Rudnic, E.M. Novel
569 Formulation of THC and CBN in a Repeat-Action Tablet Improves Objective and Subjective Measurements of Sleep. *Am J*
570 *Endocannabinoid Medicine* **2021**, *3*, 12-18.
- 571 13. Walsh, J.H.; Maddison, K.J.; Rankin, T.; Murray, K.; McArdle, N.; Ree, M.J.; Hillman, D.R.; Eastwood, P.R. Treating
572 insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine
573 compared with placebo. *Sleep* **2021**, *44*, doi:10.1093/sleep/zsab149.
- 574 14. Corroon, J. Cannabinol and Sleep: Separating Fact from Fiction. *Cannabis and cannabinoid research* **2021**, *6*, 366-371,
575 doi:10.1089/can.2021.0006.
- 576 15. Gottesmann, C. GABA mechanisms and sleep. *Neuroscience* **2002**, *111*, 231-239, doi:10.1016/s0306-4522(02)00034-9.
- 577 16. Ngo, D.H.; Vo, T.S. An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid. *Molecules (Basel,*
578 *Switzerland)* **2019**, *24*, doi:10.3390/molecules24152678.
- 579 17. Saeed, M.; Naveed, M.; Arif, M.; Kakar, M.U.; Manzoor, R.; Abd El-Hack, M.E.; Alagawany, M.; Tiwari, R.; Khandia, R.;
580 Munjal, A.; et al. Green tea (*Camellia sinensis*) and l-theanine: Medicinal values and beneficial applications in humans-A
581 comprehensive review. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* **2017**, *95*, 1260-1275,
582 doi:10.1016/j.biopha.2017.09.024.
- 583 18. Kim, S.; Jo, K.; Hong, K.B.; Han, S.H.; Suh, H.J. GABA and l-theanine mixture decreases sleep latency and improves
584 NREM sleep. *Pharmaceutical biology* **2019**, *57*, 65-73, doi:10.1080/13880209.2018.1557698.
- 585 19. Ives, A. An experimental inquiry in the chemical properties and economical and medicinal virtues of the *Humulus*
586 *lupulus*, or common hop. *Ann. Philos* **1821**, *2*, 194-202.
- 587 20. Biendl, M.; Pinzl, C. Hops and health. *MBAA TQ* **2009**, *46*, 1-7.
- 588 21. Nuutinen, T. Medicinal properties of terpenes found in *Cannabis sativa* and *Humulus lupulus*. *European journal of*
589 *medicinal chemistry* **2018**, *157*, 198-228.
- 590 22. Franco, L.; Sánchez, C.; Bravo, R.; Rodriguez, A.; Barriga, C.; Juárez, J.C. The sedative effects of hops (*Humulus lupulus*),
591 a component of beer, on the activity/rest rhythm. *Acta physiologica Hungarica* **2012**, *99*, 133-139,
592 doi:10.1556/APhysiol.99.2012.2.6.
- 593 23. Benkherouf, A.Y.; Soini, S.L.; Stompor, M.; Uusi-Oukari, M. Positive allosteric modulation of native and recombinant
594 GABA(A) receptors by hops prenylflavonoids. *European journal of pharmacology* **2019**, *852*, 34-41,
595 doi:10.1016/j.ejphar.2019.02.034.
- 596 24. Carbone, K.; Gervasi, F. An Updated Review of the Genus *Humulus*: A Valuable Source of Bioactive Compounds for
597 Health and Disease Prevention. *Plants (Basel, Switzerland)* **2022**, *11*, doi:10.3390/plants11243434.
- 598 25. Xu, H.; Yuan, H.; Pan, L.; Guo, X. The Pharmacological effects of volatile oil from *Valeriana* on central nervous system.
599 *Chinese Journal of Pharmaceutical Analysis* **1997**, *17*, 399-400.
- 600 26. Li, J.; Li, X.; Wang, C.; Zhang, M.; Ye, M.; Wang, Q. The potential of *Valeriana* as a traditional Chinese medicine:
601 Traditional clinical applications, bioactivities, and phytochemistry. *Frontiers in Pharmacology* **2022**, *13*.
- 602 27. Orhan, I.E. A Review Focused on Molecular Mechanisms of Anxiolytic Effect of *Valeriana officinalis* L. in Connection with
603 Its Phytochemistry through in vitro/in vivo Studies. *Current pharmaceutical design* **2021**, *27*, 3084-3090,
604 doi:10.2174/1381612827666210119105254.
- 605 28. Bonn-Miller, M.O.; ElSohly, M.A.; Loflin, M.J.E.; Chandra, S.; Vandrey, R. Cannabis and cannabinoid drug development:
606 evaluating botanical versus single molecule approaches. *International review of psychiatry (Abingdon, England)* **2018**, *30*,
607 277-284, doi:10.1080/09540261.2018.1474730.
- 608 29. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy.
609 *Current drug targets* **2011**, *12*, 122-132, doi:10.2174/138945011793591626.

- 610 30. Wagner, H.; Ulrich-Merzenich, G. Synergy research: approaching a new generation of phytopharmaceuticals.
611 *Phytomedicine : international journal of phytotherapy and phytopharmacology* **2009**, *16*, 97-110,
612 doi:10.1016/j.phymed.2008.12.018.
- 613 31. Russo, E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British journal of*
614 *pharmacology* **2011**, *163*, 1344-1364, doi:10.1111/j.1476-5381.2011.01238.x.
- 615 32. Norman, G.R.; Sloan, J.A.; Wyrwich, K.W. Interpretation of changes in health-related quality of life: the remarkable
616 universality of half a standard deviation. *Medical care* **2003**, *41*, 582-592, doi:10.1097/01.Mlr.0000062554.74615.4c.
- 617 33. Yu, L.; Buysse, D.J.; Germain, A.; Moul, D.E.; Stover, A.; Dodds, N.E.; Johnston, K.L.; Pilkonis, P.A. Development of short
618 forms from the PROMIS™ sleep disturbance and sleep-related impairment item banks. *Behavioral sleep medicine* **2012**, *10*,
619 6-24.
- 620 34. Alvaro, P.K.; Roberts, R.M.; Harris, J.K. A Systematic Review Assessing Bidirectionality between Sleep Disturbances,
621 Anxiety, and Depression. *Sleep* **2013**, *36*, 1059-1068, doi:10.5665/sleep.2810.
- 622 35. Belendiuk, K.A.; Babson, K.A.; Vandrey, R.; Bonn-Miller, M.O. Cannabis species and cannabinoid concentration
623 preference among sleep-disturbed medicinal cannabis users. *Addictive behaviors* **2015**, *50*, 178-181,
624 doi:10.1016/j.addbeh.2015.06.032.
- 625 36. Granger, R.E.; Campbell, E.L.; Johnston, G.A. (+)- And (-)-borneol: efficacious positive modulators of GABA action at
626 human recombinant alpha1beta2gamma2L GABA(A) receptors. *Biochemical pharmacology* **2005**, *69*, 1101-1111,
627 doi:10.1016/j.bcp.2005.01.002.
- 628 37. Saleska, J.L.; Bryant, C.; Kolobaric, A.; D'Adamo, C.R.; Colwell, C.S.; Loewy, D.; Chen, J.; Pauli, E.K. The Safety and
629 Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A
630 Double-Blinded, Randomized Controlled Trial. *Journal of the American Nutrition Association* **2023**, 1-11,
631 doi:10.1080/27697061.2023.2203221.
- 632 38. Sherman, R.E.; Anderson, S.A.; Dal Pan, G.J.; Gray, G.W.; Gross, T.; Hunter, N.L.; LaVange, L.; Marinac-Dabic, D.; Marks,
633 P.W.; Robb, M.A.; et al. Real-World Evidence - What Is It and What Can It Tell Us? *The New England journal of medicine*
634 **2016**, *375*, 2293-2297, doi:10.1056/NEJMs1609216.

635 **Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual
636 author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury
637 to people or property resulting from any ideas, methods, instructions or products referred to in the content.